By IDSE News Staff
The FDA awarded a fast track designation for CP101, an encapsulated, oral fecal microbiota transplant (FMT) product (Finch Therapeutics Group) derived from healthy human donors.
It could be the first FDA-approved FMT product for patients with recurrent Clostridium difficile infections, and is currently being evaluated in Finch’s PRISM 3 study.